Gaixia Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Gaixia Liu has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Chenhao Hu
Department of General Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
2 shared publications- Chenhao Hu
Department of General Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
2 shared publications Feiyu Shi
Department of General Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
2 shared publicationsJiaqi Zhang
Center for Gut Microbiome Research, Med-X Institute, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
2 shared publications- Junjun She
Department of High Talent, Center for Gut Microbiome Research, Med-X Institute Centre, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China
2 shared publications - Lei Zhang
Northwestern Polytechnical University, Xi'an, China
2 shared publications
Latest Publications
- Open Access
- 16 May 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Methyltransferase MGMT upregulation drives metastasis by activating epithelial-mesenchymal transition in KRAS mutant colon cancer
Kirsten rat sarcoma (KRAS)-mutant colorectal cancer (CRC) is characterized by aggressive metastatic progression and profound therapeutic resistance. While direct inhibitors have emerged recently, their clinical application is often limited by rapid adaptive resistance, highlighting the urgent need to explore new therapeutic targets. Here, we identify O6-methylguanine-DNA methyltransferase (MGMT), a classical DNA repair enzyme, as a novel epigenetic facilitator of metastasis in KRAS-mutant CRC. Through integrated analyses of clinical cohorts and orthotopic metastasis models, we found that MGMT is upregulated in KRAS-mutant tumors and correlates with liver metastasis. Functionally, MGMT promotes epithelial-mesenchymal transition (EMT) and enhances metastatic capacity in vivo and in vitro. Mechanistically, we unveil a non-canonical function of MGMT in CRC: it interacts with histone H3 and reduces repressive H3K9me3 marks at the promoter of the epithelial-mesenchymal transition master regulator TWIST1, thereby activating its transcription. Importantly, we demonstrate that targeting MGMT sensitizes KRAS-mutant colorectal cancer to anti-EGFR therapy in preclinical models, providing a novel combinatorial strategy for this recalcitrant cancer subtype. Our study redefines MGMT as a multifaceted chromatin-modifying protein and establishes it as a promising therapeutic vulnerability to bypass resistance in KRAS-mutant CRC.
- 16 May 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessMethyltransferase MGMT upregulation drives metastasis by activating epithelial-mesenchymal transition in KRAS mutant colon cancer
Kirsten rat sarcoma (KRAS)-mutant colorectal cancer (CRC) is characterized by aggressive metastatic progression and profound therapeutic resistance. While direct inhibitors have emerged recently, their clinical application is often limited by rapid adaptive resistance, highlighting the urgent need to explore new therapeutic targets. Here, we identify O6-methylguanine-DNA methyltransferase (MGMT), a classical DNA repair enzyme, as a novel epigenetic facilitator of metastasis in KRAS-mutant CRC. Through integrated analyses of clinical cohorts and orthotopic metastasis models, we found that MGMT is upregulated in KRAS-mutant tumors and correlates with liver metastasis. Functionally, MGMT promotes epithelial-mesenchymal transition (EMT) and enhances metastatic capacity in vivo and in vitro. Mechanistically, we unveil a non-canonical function of MGMT in CRC: it interacts with histone H3 and reduces repressive H3K9me3 marks at the promoter of the epithelial-mesenchymal transition master regulator TWIST1, thereby activating its transcription. Importantly, we demonstrate that targeting MGMT sensitizes KRAS-mutant colorectal cancer to anti-EGFR therapy in preclinical models, providing a novel combinatorial strategy for this recalcitrant cancer subtype. Our study redefines MGMT as a multifaceted chromatin-modifying protein and establishes it as a promising therapeutic vulnerability to bypass resistance in KRAS-mutant CRC.
- Open Access
- 2 July 2024
- Published by Elsevier in Cancer Letters
- Vol. 598, 217087
Appendix removal affects the subsequent cancer risk in Asian adults: A territory-wide population-based cohort study
- 2 July 2024
- Published by Elsevier in Cancer Letters
- Vol. 598, 217087
Open AccessAppendix removal affects the subsequent cancer risk in Asian adults: A territory-wide population-based cohort study
- 4 February 2023
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 47 (3) , 102090
Association between prior appendectomy and the risk and course of Crohn's disease: A systematic review and meta-analysis
- 4 February 2023
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 47 (3) , 102090
Association between prior appendectomy and the risk and course of Crohn's disease: A systematic review and meta-analysis
- 1 July 2012
- Published by Elsevier in Applied Surface Science
- Vol. 258 (18) , 7166-7173
Synthesis of acid-functionalized composite via surface deposition of acid-containing amorphous carbon
- 1 July 2012
- Published by Elsevier in Applied Surface Science
- Vol. 258 (18) , 7166-7173
Synthesis of acid-functionalized composite via surface deposition of acid-containing amorphous carbon